Report Ocean presents a new report on subdermal contraceptive implants market size, share, growth, industry trends, and forecast 2030, covering various industry elements and growth trends helpful for ...
April 26, 2010 (Barcelona, Spain) — The gonadotropin-releasing hormone (GnRH) agonist histrelin acetate (VantasR), administered as a 50 mg subdermal implant once yearly, retained its effectiveness ...
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evaluating the safety, tolerability and ...
Vivani Medical, Inc. (NASDAQ:VANI) announced that the U.S. FDA has cleared its Investigational New Drug Application for NPM-119, paving the way for the commencement of the LIBERATE-1 Phase 1 trial.
Phase 1 Data Presented Today at IAS 2019 KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today results from a Phase 1 study ...
The combination of contraceptive implants and new antiretroviral combination therapy being rolled out in Africa do not appear to have drug-drug interactions with treatment for HIV infection, ...
There are three progestin-containing subdermal implants. The first implant to be developed was Norplant, which is no longer being manufactured. Norplant had six levonorgestrel-containing capsules, and ...
IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. The arm model ("Subdermal Implant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results